Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.

van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, Heerspink HJL

Diabetes, obesity & metabolism14 May 2021Cited by 45 (Europe PMC)

PMID33908691PMCIDPMC8360098DOI10.1111/dom.14410PepBankPUB-33908691

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In obese patients with type 2 diabetes, exenatide alone did not significantly change UACR from baseline.
In plain wordsIn obese patients with type 2 diabetes, exenatide alone did not significantly change urine albumin relative to creatinine from baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeUACR change with exenatide alone
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
UACR change from baseline
−15.6%
exenatide group; 95% CI -41.4 to 21.6
Source sentences
Summary
-15.6% (95% CI -41.4, 21.6; P = 0.357) in the exenatide group
2 context sentences(design, population, supporting numbers)
Summary · context
At week 16, the mean UACR change from baseline was
Summary · context
In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with type 2 diabetes in a 16-week randomized double-blind placebo-controlled clinical trial
Report a problemFND-3390869102

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In obese patients with type 2 diabetes, exenatide plus dapagliflozin reduced UACR from baseline.
In plain wordsIn obese patients with type 2 diabetes, exenatide plus dapagliflozin lowered urine albumin relative to creatinine from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUACR change with combination
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Measurements
UACR change from baseline
−39.6%
exenatide-dapagliflozin group; 95% CI -58.6 to -11.9
Source sentences
Summary
At week 16, the mean UACR change from baseline was -39.6% (95% confidence interval [CI] -58.6, -11.9; P = 0.001) in the combined exenatide-dapagliflozin group
1 context sentence(design, population, supporting numbers)
Summary · context
In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with type 2 diabetes in a 16-week randomized double-blind placebo-controlled clinical trial
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3390869101
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In obese patients with type 2 diabetes, UACR did not differ significantly between exenatide plus dapagliflozin and placebo.
In plain wordsIn obese patients with type 2 diabetes, urine albumin relative to creatinine did not differ significantly between combination treatment and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeUACR combination versus placebo
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Measurements
UACR difference vs placebo
−32.2%
exenatide-dapagliflozin group; 95% CI -60.7 to 16.9
Source sentences
Summary
Compared to placebo, UACR difference at week 16 in the exenatide-dapagliflozin group was -32.2% (95% CI -60.7, 16.9; P = 0.159).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with type 2 diabetes in a 16-week randomized double-blind placebo-controlled clinical trial
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3390869103
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In obese patients with type 2 diabetes, exenatide plus dapagliflozin showed a nonsignificant acute creatinine-estimated GFR dip versus placebo.
In plain wordsIn obese patients with type 2 diabetes, the combination showed no significant creatinine-based kidney filtration difference versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCreatinine-estimated GFR
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Measurements
Creatinine-estimated GFR difference vs placebo
−4 mL/min/1.73 m2
exenatide-dapagliflozin group; 95% CI -9.3 to 1.2
Source sentences
Summary
Compared to placebo, in the exenatide-dapagliflozin group, an acute dip in estimated GFR was observed with creatinine-estimated GFR (-4.0 mL/min/1.73 m² [95% CI -9.3, 1.2]; P = 0.129) and cystatin C-estimated GFR (-10.4 mL/min/1.73 m² [95% CI -14.9, -5.8]; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with type 2 diabetes in a 16-week randomized double-blind placebo-controlled clinical trial
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3390869105
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In obese patients with type 2 diabetes, exenatide plus dapagliflozin acutely reduced cystatin C-estimated GFR versus placebo.
In plain wordsIn obese patients with type 2 diabetes, the combination acutely reduced cystatin-based kidney filtration compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCystatin C-estimated GFR
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Measurements
Cystatin C-estimated GFR difference vs placebo
−10.4 mL/min/1.73 m2
exenatide-dapagliflozin group; 95% CI -14.9 to -5.8
Source sentences
Summary
Compared to placebo, in the exenatide-dapagliflozin group, an acute dip in estimated GFR was observed with creatinine-estimated GFR (-4.0 mL/min/1.73 m² [95% CI -9.3, 1.2]; P = 0.129) and cystatin C-estimated GFR (-10.4 mL/min/1.73 m² [95% CI -14.9, -5.8]; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with type 2 diabetes in a 16-week randomized double-blind placebo-controlled clinical trial
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3390869106
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In obese patients with type 2 diabetes, exenatide plus dapagliflozin did not significantly change KIM-1:creatinine ratio versus placebo.
In plain wordsIn obese patients with type 2 diabetes, the combination did not significantly change a kidney injury marker compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeKIM-1:creatinine ratio
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Measurements
KIM-1:Cr difference vs placebo
−43.8%
exenatide-dapagliflozin group; 95% CI -73.5 to 18.9
Source sentences
Summary
The mean KIM-1:Cr difference in the combined treatment arm versus placebo was -43.8% (95% CI -73.5, 18.9; P = 0.129).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with type 2 diabetes in a 16-week randomized double-blind placebo-controlled clinical trial
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3390869107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.